Clinical Trials Directory

We are doing this study to find out if an investigational drug called CG0070 (the study drug) is safe and effective for patients who have NMIBC that does not respond to BCG treatment.

We are doing this study to learn if a combination of chemotherapies and immunotherapies (carboplatin, cabazitaxel, nivolumab and ipilimumab) slows cancer growth in patients with metastatic neuroendocrine or aggressive variant prostate cancer.

We also want to learn about the types of side effects that patients have while they are taking these study drugs together.

If you choose to join this study, you will:<ul>
<li>Give a saliva sample</li>
<li>Have a genetic test using the Color Genomics 30 gene hereditary panel test</li></ul>

We are doing this study to find out if neratinib combined with palbociclib is better than neratinib alone when it comes to treating HER2-positive tumors.

We are doing this study to find out if adding a drug called tucatinib to the usual treatment of T-DM1 on its own can help prevent breast cancer from returning.

We are doing this study to compare the study drug, lutetium-177 edotreotide, to existing standard-of-care therapies.

We want to find out if a study drug called larotrectinib is an effective treatment for brain tumors in children and young adults. We want to learn how well it works to shrink brain tumors when used alone or when given with standard chemotherapy or after radiation therapy.

We are doing this study to find out if the use of continuous glucose monitors (CGMs) is worthwhile to help breast cancer patients and their providers monitor for hyperglycemia, or high blood sugar, during chemotherapy. A CGM is a small, wearable sensor that is attached to the skin to frequently measure your blood sugar level, and can share the measurements to your smartphone and to your medical team.